c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: Implications for anticancer therapy

Cancer Research

Volumn 69, Issue 19, 2009, Pages 7491-7494

  Lin, Chen Ju ^a   Malina, Abba ^a   Pelletier, Jerry ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; HIPPURISTANOL; INITIATION FACTOR 4F; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; RAPAMYCIN; UNCLASSIFIED DRUG;

BURKITT LYMPHOMA; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; DEREGULATION; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; INHIBITION KINETICS; LYMPHOMA; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; NEOPLASM; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; RNA TRANSLATION; TRANSLATION REGULATION; UPREGULATION;

ANIMALS; CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; EUKARYOTIC INITIATION FACTOR-4F; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 70350241382     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0813     Document Type: Review

References (26)

1. Kretzner L, Blackwood EM, Eisenman RN. Myc and Max proteins possess distinct transcriptional activities. Nature 1992;359:426-429
2. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H. Sequence-specific DNA binding by the c-Myc protein. Science 1990;250:1149-1151 (Pubitemid 120031826)
3. Blackwell TK, Huang J, Ma A, et al. Binding of myc proteins to canonical and noncanonical DNA sequences. Mol Cell Biol 1993;13:5216-5224 (Pubitemid 23260626)
4. Hayward WS, Neel BG, Astrin SM. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 1981;290:475-480
5. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18:3004-3016
6. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000;16:653-699 (Pubitemid 32037520)
7. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999;13:2658-2669
8. Fernandez PC, Frank SR, Wang L, et al. Genomic targets of the human c-Myc protein. Genes Dev 2003; 17:1115-1129 (Pubitemid 36534986)
9. Orian A, van Steensel B, Delrow J, et al. Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. Genes Dev 2003;17:1101-1114 (Pubitemid 36534985)
10. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 1997;8:1039-1048 (Pubitemid 27433292)
11. Iritani BM, Eisenman RN. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci U S A 1999;96:13180-13185
12. Duncan R, Milburn SC, Hershey JW. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. J Biol Chem 1987; 262:380-388 (Pubitemid 17000032)
13. Jones RM, Branda J, Johnston KA, et al. An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Mol Cell Biol 1996;16:4754-4764 (Pubitemid 26272129)
14. Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res 2008;68: 5326-5334
15. Eilers M, Picard D, Yamamoto KR, Bishop JM. Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature 1989;340:66-68 (Pubitemid 19172604)
16. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004;23: 3189-3199 (Pubitemid 38638830)
17. Meric F, Hunt KK. Translation initiation in cancer: a novel target for therapy. Mol Cancer Ther 2002;1:971-979
18. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332-337 (Pubitemid 38418805)
19. Avdulov S, Li S, Michalek V, et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004;5:553-563 (Pubitemid 38748917)
20. Gingras AC, Gygi SP, Raught B, et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 1999;13:1422-1437 (Pubitemid 29270247)
21. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. S6K1- and hTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006;314: 467-471 (Pubitemid 44628968)
22. Ravitz MJ, Chen L, Lynch M, Schmidt EV. c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation. Cancer Res 2007;67:11209-11217 (Pubitemid 350248546)
23. Mills JR, Hippo Y, Robert F, et al. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A 2008;105:10853-10858
24. Bordeleau ME, Mori A, Oberer M, et al. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Natl Chem Biol 2006;2:213-220
25. Graff JR, Konicek BW, Vincent TM, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007;117:2638-2648
26. Bordeleau ME, Robert F, Gerard B, et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 2008;118:2651-2660 (Pubitemid 351949792)